CR20160119A - Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística - Google Patents

Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística

Info

Publication number
CR20160119A
CR20160119A CR20160119A CR20160119A CR20160119A CR 20160119 A CR20160119 A CR 20160119A CR 20160119 A CR20160119 A CR 20160119A CR 20160119 A CR20160119 A CR 20160119A CR 20160119 A CR20160119 A CR 20160119A
Authority
CR
Costa Rica
Prior art keywords
treatment
pharmaceutical compositions
fibrosis
chysical
new compounds
Prior art date
Application number
CR20160119A
Other languages
English (en)
Inventor
Der Plas Steven Emiel Van
Sébastien Laurent Xavier Martina
Sébastien Jean-Jacques Cédric Dropsit-Montovert
Martin James Inglis Andrews
Hans Kelgtermans
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51300734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201317935A external-priority patent/GB201317935D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CR20160119A publication Critical patent/CR20160119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de acuerdo con la Fórmula I: (fórmula) en donde R1 es como se define en la presente. La presente invención se relaciona con compuestos y con su uso en el tratamiento de la fibrosis quística, con métodos para su producción, con composiciones farmacéuticas que comprenden a los mismos y con métodos de tratamiento de la fibrosis quística por administración de un compuesto de la invención.
CR20160119A 2013-08-08 2016-03-08 Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística CR20160119A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179671 2013-08-08
GB201317935A GB201317935D0 (en) 2013-10-10 2013-10-10 Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PCT/EP2014/066806 WO2015018823A1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators

Publications (1)

Publication Number Publication Date
CR20160119A true CR20160119A (es) 2016-07-12

Family

ID=51300734

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160119A CR20160119A (es) 2013-08-08 2016-03-08 Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística

Country Status (32)

Country Link
US (4) US9133210B2 (es)
EP (2) EP3486246A1 (es)
JP (1) JP6425724B2 (es)
KR (1) KR20160040295A (es)
CN (1) CN105658655B (es)
AU (1) AU2014304562B8 (es)
BR (1) BR112016001984A2 (es)
CA (1) CA2919776A1 (es)
CL (1) CL2016000298A1 (es)
CR (1) CR20160119A (es)
CY (1) CY1121027T1 (es)
DK (1) DK3030568T3 (es)
DO (1) DOP2016000041A (es)
ES (1) ES2691944T3 (es)
HR (1) HRP20181541T1 (es)
HU (1) HUE040366T2 (es)
IL (1) IL243600B (es)
LT (1) LT3030568T (es)
LU (1) LU92577B1 (es)
MX (1) MX2016001602A (es)
MY (1) MY176814A (es)
PE (1) PE20160286A1 (es)
PH (1) PH12016500161A1 (es)
PL (1) PL3030568T3 (es)
PT (1) PT3030568T (es)
RU (1) RU2708690C2 (es)
SG (1) SG11201600891UA (es)
SI (1) SI3030568T1 (es)
TR (1) TR201819434T4 (es)
TW (1) TWI649325B (es)
UY (1) UY35700A (es)
WO (1) WO2015018823A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
PE20160286A1 (es) * 2013-08-08 2016-05-22 Galapagos Nv DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN107922338A (zh) 2015-06-02 2018-04-17 艾伯维公司 经取代的吡啶及使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
JP2018530557A (ja) 2015-10-09 2018-10-18 アッヴィ・エス・ア・エール・エル 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用
BR112018007176A2 (pt) 2015-10-09 2018-10-16 AbbVie S.à.r.l. combinações de potenciador-corretor úteis no tratamento da fibrose cística
KR20180083323A (ko) 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
EP3359540A1 (en) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Novel compounds for treatment of cystic fibrosis
PT3394040T (pt) 2015-12-24 2022-03-24 Univ California Reguladores de cftr e seus métodos de uso
AU2017217806A1 (en) * 2016-02-12 2018-08-16 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified CFTR modulators
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018073175A1 (en) 2016-10-17 2018-04-26 AbbVie S.à.r.l. Compounds and pharmaceutical compositions thereof for use in the treatment of cystic fibrosis
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
KR102850569B1 (ko) * 2018-06-21 2025-08-26 유씨비 바이오파마 에스알엘 IgE에 의하여 유발된 질병의 치료를 위한 티오펜 유도체
CN108546266B (zh) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
CA3157798A1 (en) 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
BR112023002651A2 (pt) 2020-08-20 2023-04-04 Univ Leland Stanford Junior Métodos de tratamento de doenças respiratórias definidas por hipersecreção de muco
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
PE20241330A1 (es) 2021-09-03 2024-06-26 Genzyme Corp Compuestos de indol y metodos de uso
US12072466B1 (en) * 2021-09-30 2024-08-27 Zoox, Inc. Detecting dark objects in stray light halos
PE20250932A1 (es) * 2022-06-10 2025-04-02 Sionna Therapeutics Inc Compuestos, composiciones y metodos de uso de los mismos
KR20250091331A (ko) 2022-09-07 2025-06-20 시오나 테라퓨틱스 인크. 거대환식 화합물, 조성물, 및 이의 사용 방법
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2025132358A1 (en) 2023-12-21 2025-06-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
JP3409029B2 (ja) 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
IT1313581B1 (it) 1999-07-30 2002-09-09 Recordati Chem Pharm Derivati tienopirancarbossamidici.
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
JP2002308870A (ja) 2001-04-11 2002-10-23 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
EA200500283A1 (ru) 2002-07-29 2005-08-25 Рэнбакси Лабораториз Лимитед Производные оксазолидинона как противомикробные средства
JP2004137185A (ja) 2002-10-17 2004-05-13 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
JP2008517061A (ja) 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
DE602005014383D1 (en) 2004-12-17 2009-06-18 Hoffmann La Roche Thienopyridinderivate als allostere gaba-b-enhancer
JP5175228B2 (ja) 2006-02-15 2013-04-03 サノフイ 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007139795A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
BRPI0907925A2 (pt) 2008-02-25 2015-07-28 Merck Patent Gmbh Ativadores de glicoquinase.
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US8822462B2 (en) 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
EP2421528A4 (en) 2009-04-20 2012-10-17 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
AU2012329913A1 (en) 2011-10-27 2014-05-22 Astellas Pharma Inc. Aminoalkyl-substituted N-thienyl benzamide derivative
WO2013129435A1 (ja) 2012-02-28 2013-09-06 協和発酵キリン株式会社 縮環チオフェン誘導体
PT2873658T (pt) 2012-07-12 2018-12-05 Nissan Chemical Corp Composto de amida substituída com oxima e agente de controlo de pragas
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
PE20160286A1 (es) * 2013-08-08 2016-05-22 Galapagos Nv DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA

Also Published As

Publication number Publication date
EP3486246A1 (en) 2019-05-22
PE20160286A1 (es) 2016-05-22
CY1121027T1 (el) 2019-12-11
SG11201600891UA (en) 2016-03-30
US20180221334A1 (en) 2018-08-09
CN105658655A (zh) 2016-06-08
US9895347B2 (en) 2018-02-20
IL243600A0 (en) 2016-02-29
PL3030568T3 (pl) 2019-03-29
UY35700A (es) 2015-03-27
TWI649325B (zh) 2019-02-01
HUE040366T2 (hu) 2019-03-28
SI3030568T1 (sl) 2019-02-28
CL2016000298A1 (es) 2016-11-11
RU2708690C2 (ru) 2019-12-11
PH12016500161A1 (en) 2016-04-25
US9351955B2 (en) 2016-05-31
CN105658655B (zh) 2018-11-13
AU2014304562A8 (en) 2018-07-05
TR201819434T4 (tr) 2019-01-21
LU92577B1 (fr) 2015-02-24
EP3030568A1 (en) 2016-06-15
JP2016527296A (ja) 2016-09-08
US20160317493A1 (en) 2016-11-03
US10568867B2 (en) 2020-02-25
AU2014304562B2 (en) 2018-05-17
CA2919776A1 (en) 2015-02-12
MX2016001602A (es) 2016-12-15
RU2016107721A3 (es) 2018-04-28
US9133210B2 (en) 2015-09-15
BR112016001984A2 (pt) 2017-08-01
RU2016107721A (ru) 2017-09-13
ES2691944T3 (es) 2018-11-29
KR20160040295A (ko) 2016-04-12
WO2015018823A1 (en) 2015-02-12
EP3030568B1 (en) 2018-09-19
US20150045327A1 (en) 2015-02-12
DOP2016000041A (es) 2016-04-04
TW201536791A (zh) 2015-10-01
AU2014304562A1 (en) 2016-02-04
LT3030568T (lt) 2018-12-27
MY176814A (en) 2020-08-21
HK1222861A1 (en) 2017-07-14
IL243600B (en) 2019-05-30
JP6425724B2 (ja) 2018-11-21
HRP20181541T1 (hr) 2018-11-16
AU2014304562B8 (en) 2018-07-05
US20160022633A1 (en) 2016-01-28
DK3030568T3 (en) 2019-01-07
PT3030568T (pt) 2018-12-24

Similar Documents

Publication Publication Date Title
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
UY36702A (es) Piridinas sustituidas y métodos de uso
CR20150370A (es) Compuestos antivirales
UY35469A (es) Moduladores de p2x7
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY35447A (es) Moduladores de p2x7
UY35467A (es) Compuestos orgánicos
ECSP13013074A (es) Nuevos derivados de piridina
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
CR20150440A (es) Nuevos derivados de piridina
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
ECSP15013883A (es) Benzamidas
CR20150511A (es) Nuevos derivados de purina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20160448A (es) Nuevos derivados de piridina